<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516213</url>
  </required_header>
  <id_info>
    <org_study_id>19.02.CLI</org_study_id>
    <nct_id>NCT04516213</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Tolerance and Safety of a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)</brief_title>
  <official_title>An Open-label, Single-arm Study to Evaluate the Tolerance and Safety of a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG) in the Nutritional Management of Tube-fed Children Aged 1-4 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicenter, Open-label, Single-arm study evaluating the Tolerance and Safety of a&#xD;
      Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG) in the Nutritional&#xD;
      Management of Tube-fed Children Aged 1-4 Years over a 7 day period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI Intolerance</measure>
    <time_frame>7 Days</time_frame>
    <description>Occurrence of gastrointestinal intolerance (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>7 Days</time_frame>
    <description>Frequency and nature of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy Requirements Met</measure>
    <time_frame>7 Days</time_frame>
    <description>The daily percentage of energy requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>7 Days</time_frame>
    <description>The change in weight over a 7-day period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Enteral Nutrition</condition>
  <arm_group>
    <arm_group_label>Enteral formula tube feeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enterally fed children, ages 1-4, with established enteral feeding access</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Enteral Formula With (PHGG)</intervention_name>
    <description>Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)</description>
    <arm_group_label>Enteral formula tube feeding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent from subject and/or subject's parents&#xD;
             or legally authorized representatives (LAR).&#xD;
&#xD;
          -  Male or female, 12 to 48 months of age, inclusive.&#xD;
&#xD;
          -  Subjects requiring enteral feeding for &gt; 7 days (in hospital, long-term care facility&#xD;
             or at home).&#xD;
&#xD;
          -  Subjects receiving enteral tube-feeding (nasogastric feeding tube or percutaneous&#xD;
             endoscopic gastrostomy [PEG] tube) to provide 90% or more of their nutritional needs&#xD;
             at the time of study entry.&#xD;
&#xD;
          -  Subject is clinically stable (i.e. absence of any significant gastrointestinal&#xD;
             symptoms during the past 7 days), in the opinion of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects receiving partial or total parenteral nutrition (e.g. for short bowel&#xD;
             syndrome and other causes of intestinal failure).&#xD;
&#xD;
          -  Subjects with ongoing or intermittent significant gastrointestinal symptoms during the&#xD;
             7 days before enrollment.&#xD;
&#xD;
          -  Oncology patients recovering from chemotherapy or radiotherapy for hematological&#xD;
             malignancies or solid tumors (last treatment within 3 months of enrollment).&#xD;
&#xD;
          -  Congenital immunodeficiency syndromes (SCID etc).&#xD;
&#xD;
          -  Cystic fibrosis and other causes of fat malabsorption (lymphatic&#xD;
             malformations/lymphangiectasis).&#xD;
&#xD;
          -  Subjects with any clinically significant condition (e.g. severe malnutrition,&#xD;
             congenital heart disease, etc) that, in the investigator's opinion, would preclude&#xD;
             inclusion in the study.&#xD;
&#xD;
          -  Subjects at risk for poor compliance to the study protocol in the investigator's&#xD;
             opinion.&#xD;
&#xD;
          -  Currently participating in another conflicting trial or participated in an&#xD;
             investigational trial within 30 days of enrollment.&#xD;
&#xD;
          -  Known hypersensitivity to PHGG or to any other ingredients in the investigational&#xD;
             product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Minor, MMS, PA-C</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Center for GI and Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Center for GI and Nutrition</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care - Huntsman Cancer Institute (HCI)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113-1125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

